Skip to main content
PMC home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
letter
. 2021 Jan 18;64(4):660–663. doi: 10.1007/s11427-020-1871-4

Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19

Qiuyu Li 1,#, Cheng Cui 2,#, Fei Xu 3,#, Jianping Zhao 4, Nan Li 5, Haichao Li 6, Tianbing Wang 7, Hua Zhang 5, Na Liu 2,8, Yudong Wei 2, Xiaoye Niu 2, Yan Xu 2, Jianping Dong 8, Xueting Yao 2, Xiaohong Wang 1, Yahong Chen 1, Haiyan Li 2,9, Chunli Song 10, Jie Qiao 10, Dongyang Liu 2,✉, Ning Shen 1,✉
PMCID: PMC7816738  PMID: 33471276

The content is available as a PDF (745.2 KB).

Electronic supplementary material

Supplementary Method (366KB, pdf)
Supporting Information (118.7KB, pdf)
Supporting Information (502.8KB, pdf)

Acknowledgements

We thank the trial team members at Peking University First Hospital, Peking University People’s Hospital, the First Affiliated Hospital of Nanchang University and Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. We thank Dr. Yongchang Sun, Dr. Jinxia Zhao, Dr. Hongmei Jing, Dr. Xiaoguang Li, Dr Yahong Wang, Dr. Qinggang Ge, Dr. Chen Yao, Dr. Xiaoyan Yan, Dr. Wenle Zhao, Dr. Naiqing Zhao, Dr. Cheng Lv, Dr. Zijian Hu, Dr. Chang Liu and Dr. Lei Wang for the scientific discussion. We thank Shanghai Pharmaceutical Co., Ltd. and Guangdong ZhongSheng Pharmaceutical Co., Ltd. for providing the research drug. We thank all the members of the drug clinical trial center of Peking University Third Hospital for the whole project. This work was supported by MOST (Ministry of Science and Technology of the People’s Republic of China) foundation for SARS-CoV-2 Research (2020YFC0844500), the “13th Five-Year” National Science and Technology Major Project of China (2017ZX09101001-002-001, 2017ZX09304012), and Peking University Health Center Foundation for Combating the Pandemic Programs (BMU2020HKYZX011).

Footnotes

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Contributed equally to this work

Contributor Information

Dongyang Liu, Email: liudongyang@vip.sina.com.

Ning Shen, Email: shenning1972@126.com.

References

  1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung K SM, Lau EHY, Wong JY, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207. doi: 10.1056/NEJMoa2001316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763. doi: 10.1016/j.ebiom.2020.102763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Moon C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020;20:277. doi: 10.1038/s41577-020-0304-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Piconi S, Parisotto S, Rizzardini G, Passerini S, Terzi R, Argenteri B, Meraviglia P, Capetti A, Biasin M, Trabattoni D, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood. 2011;118:3263–3272. doi: 10.1182/blood-2011-01-329060. [DOI] [PubMed] [Google Scholar]
  7. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–768. doi: 10.1093/cid/ciaa248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847. doi: 10.1111/jth.14768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:1849. doi: 10.1136/bmj.m1849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol. 2018;195:1–7. doi: 10.1016/j.clim.2018.07.003. [DOI] [PubMed] [Google Scholar]
  11. Vaninov N. In the eye of the COVID-19 cytokine storm. Nat Rev Immunol. 2020;20:277. doi: 10.1038/s41577-020-0305-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Method (366KB, pdf)
Supporting Information (118.7KB, pdf)
Supporting Information (502.8KB, pdf)

Articles from Science China. Life Sciences are provided here courtesy of Nature Publishing Group

RESOURCES